Healthy Returns: J&J cell therapy gains edge over Bristol Myers rival
J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai’s approach to AI.
Source: cnbc.com
Rick Bienkowski News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Rick Bienkowski. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Rick Bienkowski Today - Breaking & Trending Today
Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival
J&J’s cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai’s approach to...
Source: nbcphiladelphia.com
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges - bluebird bio (NASDAQ:BLUE)
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market.
Source: benzinga.com
10 Stocks That Could 10X Over the Next 10 Years
In this article, we will be taking a look at 10 stocks that could 10x over the next 10 years.
Source: insidermonkey.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Intellia Therapeutics' First Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
Source: insidermonkey.com